Open AccessImpact of parietal cell autoantibodies and non-organ-specific autoantibodies on the treatment outcome of patients with hepatitis C virus infection: A pilot study
Author(s) -
Nikolaos Gatselis,
Sarah P. Georgiadou,
Nikos Tassopoulos,
Kalliopi Zachou,
Christos Liaskos,
Angelos Hatzakis,
Georgios N. Dalekos
Publication year - 2005
Publication title -
world journal of gastroenterology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.427
H-Index - 155
eISSN - 2219-2840
pISSN - 1007-9327
DOI - 10.3748/wjg.v11.i4.482
Subject(s) - autoantibody , medicine , immunology , hepatitis c virus , hepatitis c , antibody , anti nuclear antibody , alpha interferon , titer , virus , interferon
Various side effects have been reported in patients infected with hepatitis C virus (HCV) who were treated with interferon-alpha (IFN-alpha), including the appearance or exacerbation of underlying autoimmune diseases and the development of a variety of organ and non-organ specific autoantibodies (NOSA). However, very few studies in adults have been strictly designed to address: whether the prevalence and the titre of organ and NOSA in serial samples of HCV-treated patients were affected by IFN-alpha, and the impact of these autoantibodies on the treatment outcome of HCV patients.